UNSPSC 51312104: Lodoxamide

This classification denotes a mast cell stabilizer with the molecular formula C11H6ClN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SPU695OD73, chemically known as n,n-(2-chlor-5-cyan-3-phenylen)dioxamsaeure but generally known as lodoxamide, which bears US NIH Compound Identifier 44564. European Medicines Agency schedules Lodoxamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08553MIG.

UNSPSC 51312104 Lodoxamide is a Commodity code nominally for a specific ophthalmic antihistamine, but recent state and local solicitations tagged with this code do not align with that scope—instead, they reflect procurement of pharmaceutical products and systems across a broad range of therapeutic categories, including naloxone, generic multi-source pharmaceuticals, and over-the-counter products. State and local issuing bodies are treating the code as a catch-all pharmaceutical procurement mechanism rather than targeting a single active ingredient. The work being solicited includes annual supply contracts for naloxone and drug deactivation systems, cooperative purchasing agreements for generic pharmaceuticals distributed through authorized wholesalers, and exploratory requests for information on direct-to-manufacturer prescription programs. Issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving participating state and local government facilities including Oregon).

Geographic activity centers on Florida, Texas, and Minnesota, with the Minnesota cooperative vehicle supporting a multi-state footprint. Representative recent solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with pricing weighted 75 percent on competitiveness and 10 percent on fixed pricing; and the Texas Health and Human Services Commission's Request for Information HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The code shows material recent activity but with a mismatch between its nominal scope and actual procurement—vendors pursuing this code should monitor whether state and local agencies continue to use it for broad pharmaceutical supply or if categorization tightens to match the code's stated definition.